(ANAB) – Press Releases
-
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
-
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
-
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
-
Anaptys Named a BioSpace 2024 Best Places to Work Winner
-
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
-
Anaptys Announces Participation in November Investor Conferences
-
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
-
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
-
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
-
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
-
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
-
AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
-
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
-
AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
-
AnaptysBio Announces Participation in Upcoming Investor Conferences
-
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
-
AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)
-
AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)
-
AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors
-
AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors
-
AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survi
-
AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survi
-
AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-
AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-
AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference
-
AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference
-
AnaptysBio Announces Stock Repurchase Plan
-
AnaptysBio Announces Stock Repurchase Plan
-
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
-
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
-
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
-
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
-
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference
-
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference
-
AnaptysBio to Participate in Upcoming November Investor Conferences
-
AnaptysBio to Participate in Upcoming November Investor Conferences
-
AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update
-
AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update
-
AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials
-
AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials
-
Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors
-
Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors
-
AnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million
-
AnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million
-
AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa
-
AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa
-
AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update
-
AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update
-
AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference
Back to ANAB Stock Lookup
